No Data
No Data
New Analyst Forecast: $JAGX Given $12.98 Price Target
Jaguar Health to Present Initial Results From the Proof-of-Concept Study of Crofelemer for the Rare Diseases Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome With Intestinal Failure (SBS-IF) During an April 30 Investor Webcast
Trending Stocks Today | Baijiayun Soars 74.33%
12 Health Care Stocks Moving In Thursday's Intraday Session
Jaguar Health's Napo Reports Preliminary Results From IIT Trial of Crofelemer
Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health's Crofelemer to Be Presented at April 2025 ELITE PED-GI Congress
Raminator : You got your own stock now, too! I knew you'll be running for president in 2028
Jaguar8 OP Raminator : you crack me up